Frontline KCyd safe, effective in high-risk multiple myeloma
13 Sep 2021
bởiTristan Manalac
In transplant-eligible patients with high-risk newly diagnosed multiple myeloma (NDMM), frontline treatment with carfilzomib, cyclophosphamide, and dexamethasone (KCyd) is safe and effective, inducing high rates of treatment response without a heavy burden of adverse events (AEs), according to a recent Singapore study.
